Assessment, Pricing
1 / 21

Assessment, Pricing of Pharmaceuticals in France - PowerPoint PPT Presentation

  • Uploaded on

Assessment, Pricing of Pharmaceuticals in France. Dr. François Meyer Director, Healthcare Products and Procedures Assessment Haute Autorité de santé AIFA March 2007. Introducing a New Drug. Introducing a new drug in the healthcare system in France : 1 st step: Marketing authorization.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Assessment, Pricing of Pharmaceuticals in France' - giles

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Assessment pricing of pharmaceuticals in france

Assessment, Pricing of Pharmaceuticals in France

Dr. François MeyerDirector, Healthcare Products and Procedures AssessmentHaute Autorité de santéAIFA March 2007

Introducing a new drug
Introducing a New Drug

Introducing a new drug in the healthcare system in France :

  • 1st step: Marketing authorization.

    • Assessment : CHMP / EMEA / Afssaps

    • Decision : European Commission / Afssaps

  • 2nd step: Introduction into national healthcare systems

    • Assessment: « Health Technology Assessment »Some common principles, many national specificities

    • Decision: Country specific

    • France : “Formulary” = Positive list of reimbursed drugs

F. Meyer AIFA March 2007

Medicinal products in france
Medicinal Products in France

European Medicines Agency /Afssaps benefit/risk assessment

European Commission /Afssaps : Marketing Authorization

Ag. Française de sécurité

sanitaire des produits de santé

Transparency Committee (TC): medical benefit, added value, importance for public health, target population

Haute Autorité de santé

Healthcare Products Economic Committee: agreement / price -volumes

Public Price

Nat. Health Insurance

Level of co-payment

Minister: inscription

Ministre de la santé et de la SS

Product Launch

Advertising Control

  • Pharmacovigilance, Risk Management Plans

  • Observational Studies

Periodic Reassessment

F. Meyer AIFA March 2007

The has new body created in 2005
The HAS, new body created in 2005

HAS = French National Authority for Health, created 2005


Chair:Prof. L. Degos

7 committees


Practice appraisalCPD

Managing directorMr François Romaneix




Disease management

Healthcare procedures and Products Assessment

Information Communi-cation

General secreta-riat

Network of experts and health professionals throughout France

F. Meyer AIFA March 2007

Hta procedures in france
HTA procedures in France




HAS opinion


Economic Committee

Review of available data

Dossier from Pharma-ceutical


  • HAS Transparency Committee

  • + Health Professionals

  • HAS internal assessors

Working Group for Public Health

F. Meyer AIFA March 2007

Criteria for drug appraisal
Criteria for Drug Appraisal

HAS performs medicinal products appraisal according to criteria defined in French regulation

  • cost-effectiveness assessment not part of the « legal » criteria

  • SERVICE MEDICAL RENDU (SMR) = Actual Benefit 

    • « Clinical benefit »

      • severity of the disease

      • clinical effectiveness

    • « Benefit to Public Health » :

      • Impact on Health Status of the global population, Impact on Healthcare organisation and/or Use of healthcare resources...

  • AMELIORATION DU SMR (ASMR) Improvement in Actual Benefit

    • Comparison to other existing therapies

    • 4-level scale: from MAJOR improvement (ASMR I) to minor improvement (ASMR IV)

    • No improvement over existing therapies : (ASMR V)

F. Meyer AIFA March 2007

Criteria for pricing
Criteria for Pricing

  • Criteria for drug pricing

    • Pricing : Economic Committee for Healh Products = contract negociating committee.

    • Strong link with appraisal results on added value

      • no added value (ASMR V) : listed only if they bring some savings to the medial treatment

      • added value (ASMR I to IV) : Price higher than comparators can be accepted

    • Price/volumes agreement : Target population, as assessed by HAS, is taken into account.

    • Innovative drugs : Price deposit instead of negotiation, faster access and « European » price guaranteed

    • Incremenal progress taken into account : Price deposit open to Drugs with minor improvent of actual benefit. Pharmaco-economic studies: optional, only on a case by case basis

F. Meyer AIFA March 2007

Smr actual benefit
SMR: Actual Benefit

Actual Benefit of Drugs in 2005 and 2006

F. Meyer AIFA March 2007

Asmr improvement in actual benefit
ASMR: Improvement in Actual Benefit

Improvement in Actual Benefit for Drugs

F. Meyer AIFA March 2007

From efficacy to effectiveness
From efficacy to effectiveness…


explanatory trials

highly selected populations

comparator: often placebo

outcomes: clinical, often surrogates, adverse effects

‘is the therapy effective’


pragmatic trials

few exclusions

comparator: ‘current (best) practice’

outcomes: patient-focused, down-stream resources

‘real world added value’

Taylor R.S. Value in Health 2001;4:8-11

F. Meyer AIFA March 2007

Has opinions on drugs
HAS opinions on Drugs

  • Content :

    • Assessment of Actual benefit

    • Assessment of Added value (Improvement in actual benefit)

    • Target Population estimate

    • Advice to Prescribers : place in therapy

    • Limits of currently available data and Request for additionnal data collection

  • Availability


    • Information and communication

F. Meyer AIFA March 2007

Time from licensing to reimbursement
Time from Licensing to Reimbursement

  • Drugs can be made available before Marketing Authorisation

    • products without MA : ATU, clincical trials

    • Extension of indications : Temporary coverage (HERCEPTIN)

  • Usual procedure : Time from licensing to listing

    • Time to application submission by Pharmaceutical Company

    • Time of assessment by HAS

    • Time of price negotiation and decision publication

  • Legal limit :

    • Max. 180 days from dossier submission to decision

  • Recent trends

    • Time for issuing HAS opinion reduced

    • Average 2005: 150 days, 2006 100 days

    • 65% in less than 90 days

    • Innovative products : anticipated assessment, opinion issued within one month after licensing

    • Possible access before licensing for innovative products in severe disease

  • F. Meyer AIFA March 2007

    Some innovative drugs
    Some Innovative Drugs

    F. Meyer AIFA March 2007

    Assessment pricing of pharmaceuticals in france

    December 2004, 1000 Patients and 250 GPs per country

    Drug prescription in France

    France Germany Spain Netherlands

    No of Drugs taken during the previous 7days

    No of Visits / 12 months

    No of visits without Drug prescription (out of 100)

    F. Meyer AIFA March 2007

    Assessment pricing of pharmaceuticals in france

    F. Meyer AIFA March 2007

    French healthcare system in a nutshell
    French Healthcare System in a Nutshell

    • Unitary centralized state

    • NHI

      • Mandatory, coverage for the entire population

      • List of 30 ‘long term conditions’ with 100% coverage

        • 13% of French population, 60% of expenses

    • Supplementary Health Insurance:

      • 90 percent of the population subscribe to supplementary health insurance to cover other benefits not covered under NHI

    • Pharmaceuticals :

      • Positive list of reimbursed products

      • Supplementary insurance : 100% reimbursement rate for all listed drugs, no money to be paid to pharmacist in most cases

      • Some recent delistings of ‘old’ products

    F. Meyer AIFA March 2007

    French system in a nutshell cont
    French System in a Nutshell – Cont.

    • French healthcare organization

      • Ambulatory care : dominated by solo-based, fee-for-service private practice

      • Mix of public and propietary hospitals for acute institutional care

      • Patients free to navigate and be reimbursed under NHI.

    • Pharmaceutical expenditure

      • Percentage of total health care expenditureFrance > UK > Netherlands > Norway

      • Per capita drug expenditure Highest level in Europe

    F. Meyer AIFA March 2007

    Healthcare reform 2004
    Healthcare reform 2004

    • ‘Health insurance system losing 23,000 € a minute’..

    • Healthcare reform 2004

      • “to provide better care while spending less.”

      • creation of HAS, independent scientific body

        • HTA for drugs, medical devices, procedures

        • clinical guidelines, DMP for long term conditions

        • hospital accreditation, practice appraisal, CPD…

        • improvement in Health Professionals and Public information

      • National Union of Health Insurance Funds (UNCAM)

      • Shared, computerized medical record

      • Treating physician …

    F. Meyer AIFA March 2007

    First results perspectives
    First results, perspectives

    • Results obtained :

      • Antibiotics consumption : longstanding decrease in use

      • Generics: end of the French exception ?

      • Drugs delistings : not welcome but moreless accepted

    • Perspectives

      • Self medication

      • Rational use of pharmaceuticals

      • Improvement in methodology of drugs assessment/appraisal

      • Post marketing monitoring of drugs

        • safety

        • clinical and cost effectiveness

      • Risk sharing

    • International cooperation

      • EUnetHTA, Euroscan, HTAi, Nice-Iqwig-HAS cooperation…

      • European Commission

    F. Meyer AIFA March 2007